KEVIN GAREY to Clinical Trials as Topic
This is a "connection" page, showing publications KEVIN GAREY has written about Clinical Trials as Topic.
Connection Strength
0.345
-
Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. Expert Rev Anti Infect Ther. 2010 Jul; 8(7):747-60.
Score: 0.064
-
Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010 May; 44(5):878-84.
Score: 0.063
-
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea. Ann Pharmacother. 2008 Jun; 42(6):827-35.
Score: 0.055
-
Telithromycin: an oral ketolide for respiratory infections. Pharmacotherapy. 2001 Oct; 21(10):1204-22.
Score: 0.035
-
Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. Clin Microbiol Infect. 2020 May; 26(5):646.e1-646.e8.
Score: 0.030
-
Intravenous azithromycin. Ann Pharmacother. 1999 Feb; 33(2):218-28.
Score: 0.029
-
Trovafloxacin: an overview. Pharmacotherapy. 1999 Jan; 19(1):21-34.
Score: 0.029
-
Novel antibiotics in development to treat Clostridium difficile infection. Curr Opin Gastroenterol. 2017 01; 33(1):1-7.
Score: 0.025
-
Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs. 2010 Jul; 19(7):825-36.
Score: 0.016